Johnson & Johnson Establishes Beijing Diabetes Institute
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson has established its diabetes institute in Beijing, one of the company's first batch of four non-commercial institutes worldwide. The facility provides a free training platform for China's diabetes educators and managers. Over the next three years, the institute will work with the Ministry of Health to bring together local and overseas specialists and academics in the field to explore new standardized models with Chinese characteristics for managing the disease. Analysts believe the diabetes management model will allow China to maximize its health care resources to derive the most social benefits, especially previously idle community resources. (Click here for more - Chinese Language)
You may also be interested in...
Johnson & Johnson To Push Diabetes Management Model
At the one-year anniversary of the establishment of the Beijing Diabetes Institute (PharmAsia News, Aug. 18, 2008), Johnson & Johnson announced that it will push to improve the prevention and treatment effectiveness of diabetes and its complications. Starting with Shanghai, Zhejiang, Liaoning, Heilongjiang and Chongqing, the project will set up a highly efficient and seamless diabetes management model between hospitals and the community. Since its establishment, the Beijing diabetes institute has conducted four sessions of diabetes educator training courses in China, teaching 173 students from 25 provinces. In line with the country's healthcare reform, the institution this year began to focus on promoting its diabetes management model, which targets early detection and standardized management of the disease. (Click here for more - Chinese language)
Insider Analysis From Anand & Anand, New Dehli: What’s The Secret Behind Your Medicine? Exclusivity Or Protection Of Clinical Trial Data In India (Part 2 of 2)
By M. S. Bharath, Partner, Anand & Anand, New Dehli, India
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.